Aptose Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APS.TO research report →
Companywww.aptose.com
Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML.
- CEO
- William G. Rice
- IPO
- 1996
- Employees
- 13
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $5.95M
- P/E
- 0.79
- P/S
- 0.00
- P/B
- -0.13
- EV/EBITDA
- 0.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -23.18%
- ROIC
- -1252.52%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,913,830 · -1.90%
- EPS
- $-10.59 · -28993.41%
- Op Income
- $-25,155,789
- FCF YoY
- 37.82%
Performance & Tape
- 52W High
- $2.59
- 52W Low
- $1.02
- 50D MA
- $2.28
- 200D MA
- $2.05
- Beta
- 0.29
- Avg Volume
- 4.30K
Get TickerSpark's AI analysis on APS.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our APS.TO Coverage
We haven't published any research on APS.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APS.TO Report →